Related Experiment Videos
Long-term effect of nadolol on quantitative liver function tests in patients with cirrhosis
C Merkel1, A Gatta, D Sacerdoti
1Department of Clinical Medicine, University of Padua, Italy.
Insights
Long-term use of nadolol, a beta-blocker, did not negatively impact liver function in patients with cirrhosis and portal hypertension. This study assessed key liver function metrics over six months of treatment.
Area of Science:
- Hepatology
- Pharmacology
- Internal Medicine
Background:
- Nadolol, a non-cardioselective beta-blocker, is known to reduce portal pressure in cirrhotic patients.
- Previous studies indicated no adverse effects on liver function after one month of nadolol treatment.
- Data on the long-term hepatic effects of nadolol in cirrhosis were lacking.
Purpose of the Study:
- To evaluate the long-term effects of nadolol on liver function in patients with cirrhosis and portal hypertension.
- To assess changes in galactose elimination capacity, aminopyrine metabolic capacity, and indocyanine green (ICG) clearance after six months of nadolol treatment.
Main Methods:
- Eleven patients with cirrhosis and portal hypertension were enrolled.
- Liver function was assessed using galactose eliminating capacity, aminopyrine metabolic capacity, ICG clearance, and intrinsic hepatic clearance (parallel tube model).
- Measurements were taken before and after a six-month treatment period with nadolol, aiming for a 25% reduction in resting heart rate.
Main Results:
- No significant variations were observed in galactose eliminating capacity after six months of nadolol.
- Aminopyrine metabolic capacity remained unchanged throughout the six-month treatment period.
- Indocyanine green (ICG) clearance and intrinsic hepatic clearance showed no significant alterations.
Conclusions:
- Continuous oral administration of nadolol for six months did not impair liver function in patients with cirrhosis.
- Nadolol appears to be safe for long-term use regarding hepatic function in this patient population.
- These findings support the use of nadolol for managing portal hypertension without compromising liver function.
Abstract:
Nadolol, a non-cardioselective beta adrenoreceptor blocking agent, has been reported to decrease portal pressure without affecting liver function in cirrhotic patients treated for 1 month. There were no data about the long-term effects of nadolol on liver function. In 11 patients with cirrhosis and portal hypertension galactose eliminating capacity, aminopyrine metabolic capacity, ICG clearance and IGC intrinsic hepatic clearance according to the "parallel tube" model were measured before and after 6 months of treatment with nadolol at a dose reducing resting heart rate by approximately 25%. No significant variation in any of these parameters was found. Thus 6 months of continuous oral administration of nadolol did not further impair liver function in cirrhotics.